Neurogene (NGNE) Invested Capital (2013 - 2026)

Neurogene has reported Invested Capital for 14 years, with the latest figure at $237.8 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 18.51% year-over-year to $237.8 million; the trailing twelve-month figure through Mar 2026 stood at $237.8 million (down 18.51% YoY), and the FY2025 full-year result was $264.9 million, down 14.67% from the prior year.
• Invested Capital for Q1 2026 stood at $237.8 million, down from $264.9 million in the prior quarter.
• The five-year high for Invested Capital was $310.5 million in Q4 2024, with the low at -$183.2 million in Q3 2023.
• Historically, Invested Capital has averaged $117.1 million across 5 years, with a median of $155.1 million in 2024.
• The largest YoY upside for Invested Capital was 227.79% in 2023 against a maximum downside of 273.42% in 2023.
• Neurogene's Invested Capital stood at -$145.6 million in 2022, then soared by 227.79% to $186.1 million in 2023, then surged by 66.79% to $310.5 million in 2024, then decreased by 14.67% to $264.9 million in 2025, then dropped by 10.24% to $237.8 million in 2026.
• The last three Invested Capital figures came in at $237.8 million (Q1 2026), $264.9 million (Q4 2025), and $265.5 million (Q3 2025), per Business Quant data.